Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Human Virome01:26

Human Virome

The human body harbors a vast and diverse viral community known as the human virome. The virome includes bacteriophages that infect bacteria, and eukaryotic viruses that infect human cells. Transient dietary and environmental viruses also contribute to this dynamic ecosystem. Estimates suggest the human body may contain on the order of 10¹³ viral particles, though abundance varies widely by body site and detection method.Comprehensive characterization of the virome has become possible only with...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
International Nursing Organizations II01:28

International Nursing Organizations II

The World Health Organization (WHO) is a specialized agency of the United Nations based in Geneva. The WHO has many initiatives that center around health. Primarily, they lead global efforts to expand universal health coverage using science-based policies and programs. They are also responsible for shaping health research agendas and developing norms and standards.
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls.

Vaccine·2026
Same author

European Code Against Cancer, 5th edition - cancer-causing infections and related interventions.

Molecular oncology·2026
Same author

Preschool or Infant Human Papillomavirus Immunization?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia.

Blood advances·2025
Same author

Accelerating HPV-related cancer elimination - a meeting report.

BMC proceedings·2025
Same author

Prevalence of, and factors associated with oral sexual behaviours in men and women in Ibadan, Nigeria.

PloS one·2025

Related Experiment Video

Updated: May 16, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Implementation of human papillomavirus immunization in the developing world.

Mark A Kane1, Beatriz Serrano, Silvia de Sanjosé

  • 1Consultant on Immunization Policy, Mercer Island, WA, USA.

Vaccine
|December 4, 2012
PubMed
Summary

Cervical cancer is a major threat in developing nations. Human papillomavirus (HPV) vaccination offers crucial protection, and GAVI Alliance support is vital for its introduction in these regions.

More Related Videos

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Related Experiment Videos

Last Updated: May 16, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Area of Science:

  • Public Health
  • Vaccinology
  • Epidemiology

Background:

  • Cervical cancer is a leading cause of cancer death for women in less developed regions, particularly GAVI-eligible countries.
  • Without intervention, population growth will significantly increase cervical cancer deaths by 2025.
  • Human papillomavirus (HPV) vaccines are standard in industrialized nations, presenting a key opportunity for protection in developing countries.

Purpose of the Study:

  • To highlight the critical need for HPV vaccine introduction in developing countries.
  • To advocate for GAVI Alliance support for HPV vaccine programs.
  • To discuss strategies and challenges for HPV control in resource-limited settings.

Main Methods:

  • Review of current cervical cancer burden and prevention strategies.
  • Analysis of the role of the GAVI Alliance in vaccine introduction.
  • Discussion of immunization infrastructure, delivery strategies (e.g., school-based), and pricing models.
  • Consideration of cultural factors and optimal immunization targets (e.g., female-only vs. broader strategies).

Main Results:

  • GAVI Alliance support is the most significant opportunity for HPV vaccine access in eligible developing countries.
  • High infant immunization coverage exists in some poor countries, but HPV control strategies like screening are underdeveloped.
  • Expanding immunization infrastructure and utilizing school-based strategies show promise for achieving high HPV vaccine coverage.
  • Health economic analyses suggest female-only immunization, but optimal strategies require further consideration.

Conclusions:

  • GAVI should establish a dedicated group to facilitate HPV vaccine introduction in the developing world.
  • Middle-income countries require "tiered" pricing or regional schemes for affordable HPV vaccine access.
  • Effective HPV control necessitates adapting immunization and communication strategies to local contexts and infrastructure limitations.